XTLB: XTL Bio Market Value
XTL Biopharmaceuticals (XTLB) is developing a biopharmaceutical business with high profit growth potential driven by the mass production of drugs. The brand's academic authority in combating autoimmune failures confirms expert confidence. A strategy of creating a diversified portfolio of drugs for cancer and systemic pathologies minimizes risks. This chart illustrates the market price, currently at 0.01, reflecting the current capitalization of this developer.
Comprehensive metric breakdowns and analytics for XTL Bio (XTLB)
- stock price and consensus target price:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Total Debt to Capital XTL Biopharmaceuticals|XTLB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital XTL Biopharmaceuticals|XTLB - Company Aggregate Debts|Debt to Book Capitalization Ratio XTL Bio|XTLB - Company Long-Term Loans and Borrowings|Company Short-Term Debt XTL Biopharmaceuticals|Quick Ratio xtlbio.com
- financial results and valuation multiples details:
XTLB - Net Profit|Future Profit XTL Biopharmaceuticals|XTLB - Company Value to Net Income|Forward P/E Multiple XTL Biopharmaceuticals, Ltd.|XTLB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization XTL Bio|XTLB - Operating profit before deduction of amortization|Earnings per share for the last twelve months XTL Biopharmaceuticals|XTLB - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months xtlbio.com|XTLB - Earnings growth in current year|Net earnings per share growth forecast for next year XTL Biopharmaceuticals
Fundamental company analysis:XTLB (XTL Biopharmaceuticals Ltd.)
Small market capitalization leaves XTL Biopharmaceuticals (XTLB) vulnerable to market volatility. However, the potential for monopoly pricing power upon the success of its autoimmune disease therapy creates a significant margin of safety. This indicator reflects the total shareholder equity as the product of the share price and the number of outstanding shares. By analyzing the current capitalization level of XTL Biopharmaceuticals (XTLB), an investor assesses the market size of the business. A sharp decline in this metric signals a critical risk of investment freeze.
Key competitors
argenx - Market Valuation|Market Value BNTX (BioNTech Inc.)|ABVX - Market Value|ADMA: Market Value|PTGX: Market Capitalization|IMVT (immunovant.com) - Market Value|Market Value Kiniksa|Grifols SA - Market Valuation|Market Capitalization ADPT|CLDX (Celldex Corp) - Market Value|Market Capitalization AUPH (Aurinia Pharmaceuticals)|Market Capitalization biocryst.com BCRX|VERA - Market Value|Market Value DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp (PHVS) - Market Value|Market Valuation AbCellera Biologics Inc.|TRML (Tourmaline Bio, Inc.) - Market Capitalization|Market Capitalization precigen.com|Market Valuation PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Market Value|Market Capitalization UPB (Upstream Bio Corp)|Market Capitalization Zenas Corp (ZBIO)|IMNM - Market Value|gossamerbio.com (GOSS) - Market Valuation|KalVista Pharmaceuticals, Inc. (KALV) - Market Value|Market Valuation Septerna, Inc.|Market Valuation PVLA|Market Capitalization Savara Pharma|Market Value Rigel Pharmaceuticals (RIGL)|anaptysbio.com - Market Capitalization|Market Capitalization ATXS (Astria Therapeutics, Inc.)|enGene Holdings Inc (ENGN) - Market Value|RAPT: Market Valuation|JBIO (Aerovate Therapeutics Inc) - Market Capitalization|ACRS (Aclaris Therapeutics) - Market Valuation|KYTX: Market Value|Market Value Tiziana Life Sciences Ltd|Market Value CABA|Market Valuation VTYX (Ventyx Bio)|THTX (Theratechnologies, Inc) - Market Value|Market Capitalization AVTX (Avalo Therapeutics, Inc)|eledon.com - Market Value|Agenus Inc. - Market Capitalization|Market Capitalization Climb Bio Inc. CLYM|Zura Bio (ZURA) - Market Value|Market Value aTyr Pharmaceuticals (ATYR)|Market Value Adagene Inc|Ikena Oncology, Inc. - Market Valuation|Market Capitalization STTK|EQ (equilliumbio.com) - Market Value|Market Capitalization CNTB (Connect Biopharma Holdings Limited)|Market Capitalization Immunic Therapeutics IMUX|ATRA - Market Value|Market Value IFRX (InflaRx N.V.)|X4 Pharmaceuticals, Inc. (XFOR) - Market Value|Market Valuation Adicet Bio, Inc.|CELU (Celularity Inc) - Market Capitalization|Market Capitalization INmune Bio Corporation|Market Capitalization BRNS|Market Valuation kezarlifesciences.com KZR|Market Capitalization SABS (SAB Biotherapeutics, Inc.)|Akari Therapeutics PLC (AKTX) - Market Value|ENLV: Market Valuation|QTTB - Market Capitalization|GOVX (GeoVax Labs, Inc.) - Market Valuation|EDSA: Market Value|IBIO (iBio) - Market Capitalization|Carisma Tx (CARM) - Market Capitalization|Market Capitalization BOLT|Market Valuation hcwbiologics.com HCWB|Market Capitalization APVO (Aptevo Therapeutics Inc.)|Market Capitalization aimimmuno.com AIM|ADTX - Market Value|GRI: Market Value|XORTX (XRTX) - Market Value|HIND - Market Capitalization|Market Valuation REVB|Market Capitalization INDP (indaptusrx.com)|Market Valuation SCNI (Scinai Immunotherapeutics Ltd.)|Market Value CALI|Market Value Affimed N.V. AFMD|Allakos Inc - Market Value|HOOKIPA - Market Capitalization|IGMS: Market Value|iTeos Therapeutics, Inc. (ITOS) - Market Value|Market Valuation OCEA (Ocean Biomedical Inc)|TCBP (TC BioPharm (Holdings) PLC) - Market Capitalization|THRD: Market Value
